241 related articles for article (PubMed ID: 11268714)
1. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.
Salman S; Salman F; Satman I; Yilmaz Y; Ozer E; Sengül A; Demirel HO; Karşidağ K; Dinççağ N; Yilmaz MT
Curr Med Res Opin; 2001; 16(4):296-306. PubMed ID: 11268714
[TBL] [Abstract][Full Text] [Related]
2. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
Güvener N; Gedik O
Acta Diabetol; 1999 Jun; 36(1-2):93-7. PubMed ID: 10436259
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
[TBL] [Abstract][Full Text] [Related]
4. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
5. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
Chan JC; Chan KW; Ho LL; Fuh MM; Horn LC; Sheaves R; Panelo AA; Kim DK; Embong M
Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
[TBL] [Abstract][Full Text] [Related]
6. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Hoffmann J; Spengler M
Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
[TBL] [Abstract][Full Text] [Related]
8. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
9. Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
Zhou J; Zheng F; Guo X; Yang H; Zhang M; Tian H; Guo L; Li Q; Mo Y; Jia W
Diabetes Metab Res Rev; 2015 Oct; 31(7):725-33. PubMed ID: 25952634
[TBL] [Abstract][Full Text] [Related]
10. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes.
Mughal MA; Memon MY; Zardari MK; Tanwani RK; Ali M
J Pak Med Assoc; 2000 May; 50(5):152-6. PubMed ID: 11242714
[TBL] [Abstract][Full Text] [Related]
11. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
Inoue I; Takahashi K; Noji S; Awata T; Negishi K; Katayama S
Diabetes Res Clin Pract; 1997 Jun; 36(3):143-51. PubMed ID: 9237780
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
Hoffmann J; Spengler M
Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
Xu W; Mu Y; Zhao J; Zhu D; Ji Q; Zhou Z; Yao B; Mao A; Engel SS; Zhao B; Bi Y; Zeng L; Ran X; Lu J; Ji L; Yang W; Jia W; Weng J
Sci China Life Sci; 2017 Mar; 60(3):225-238. PubMed ID: 28271251
[TBL] [Abstract][Full Text] [Related]
14. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
Coniff RF; Shapiro JA; Seaton TB; Hoogwerf BJ; Hunt JA
Diabetes Care; 1995 Jul; 18(7):928-32. PubMed ID: 7555551
[TBL] [Abstract][Full Text] [Related]
15. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
[TBL] [Abstract][Full Text] [Related]
17. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
[TBL] [Abstract][Full Text] [Related]
18. One-year acarbose treatment raises fasting serum acetate in diabetic patients.
Wolever TM; Radmard R; Chiasson JL; Hunt JA; Josse RG; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
Diabet Med; 1995 Feb; 12(2):164-72. PubMed ID: 7743764
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.
Pareek A; Chandurkar N; Zawar S; Agrawal N
Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
